Atractylenolide I ameliorates post-infectious irritable bowel syndrome by inhibiting the polymerase I and transcript release factor and c-Jun N-terminal kinase/inducible nitric oxide synthase pathway.
AT-I could alleviate PI-IBS symptoms through downregulation of PTRF and inhibiting the JNK/ iNOS pathway. This study not only provides a scientific basis to clarify the anti-PI-IBS effect of AT-I and its mechanism but also suggests a novel promising therapeutic strategy to treat the PI-IBS.
Authors
- Cheng Kunming
- Yuan Jianan
- Chao Li (ORCID: https://orcid.org/0000-0001-6340-9960)
- Bing Li (ORCID: https://orcid.org/0000-0001-7592-1515)
- Xiang Zhang (ORCID: https://orcid.org/0000-0001-5174-0592)
- Zheng Yongqiu
- Ding Zeyu
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-02-01
- DOI
- https://doi.org/10.19852/j.cnki.jtcm.2025.01.006
- Primary Topic
- Traditional Chinese Medicine Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Horizon 2020 Framework Programme